新辅助化疗后手术对中晚期宫颈癌的临床效果

Abstract
Figure/Table
References (27)
Related Citation (15)

Download: PDF (0 KB) HTML (39 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To evaluate the clinical value after neoadjuvant chemotherapy (NACT) in patients with middle and advanced cervical cancer.Methods The clinical data of 76 patients with middle and advanced cervical cancer who underwent radical surgery of cervical cancer in our hospital from June 2016 to June 2019 were retrospectively analyzed,and divided them into research group (n=38) and control group (n=38) according to whether they received NACT before surgery.By analyzing the total effective rate after chemotherapy in the research group and the surgery time, intraoperative blood loss, lymph node metastasis rate and vascular invasion rate of the two groups of patients, the clinical value of surgery after NACT for patients with middle and advanced cervical cancer was evaluated.Results All patients in the research group successfully performed surgery after receiving NACT, with a total effective rate of 65.79% (25/38), of which CR was 0.00% (0/38), PR was 65.79% (25/38), and SD was 34.21% (13/38), PD was 0.00% (0/38).There were no significant differences in the surgery time and intraoperative blood loss between the two groups of patients (P＞0.05).The lymph node metastasis and vascular infiltration rate of the research group was lower than that of the control group,and the difference was statistically significant (P＜0.05).Conclusion NACT before radical surgery of cervical cancer has good effect on middle and advanced cervical cancer, it can reduce the size of cancer, and does not increase the difficulty of surgery, which provides another option for the treatment of patients with middle and advanced cervical cancer.

Key words： Middle and advanced cervical cancer Neoadjuvant chemotherapy Radical surgery of cervical cancer Carboplatin Paclitaxel

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HAN Yu-ying
	WANG Qing-yi
	KANG Min
	YUAN Yan-yan
	KUANG Ai-hua

Cite this article:

HAN Yu-ying,WANG Qing-yi,KANG Min, et al. Clinical effect of surgery after neoadjuvant chemotherapy on middle and advanced cervical cancer[J]. 中国当代医药, 2020, 27(23): 100-103.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I23/100

[1]	Bray F，Ferlay J，Soerjomataram I，et al.Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin，2018，68（6）：394-424.
[2]	Siegel RL，Miller KD，Jemal A.Cancer statistics，2018[J].CA Cancer J Clin，2018，68（1）：7-30.
[3]	Chen W，Zheng R，Baade PD，et al.Cancer statistics in China，2015[J].CA Cancer J Clin，2016，66（2）：115-132.
[4]	陈渊青，邓必林.宫颈癌预防模式研究进展[J].中国妇幼健康研究，2017，28（5）：615-618.
[5]	吴绘春，杨菁.新辅助化疗在宫颈癌治疗中的应用研究[J].中国妇幼健康研究，2016，27（10）：1258-1260.
[6]	Siegel RL，Miller KD，Jemal A.Cancer Statistics，2017[J].CA Cancer J Clin，2017，67（1）：7-30.
[7]	Minig I，Patrono MG，Romero N，et al.Different strategies of treatmentforuterinecervicalcarcinomastageIB2-ⅡB[J].World J Clin Oncol，2014，5（2）：86-92.
[8]	周晖，白守民，林仲秋，等.《2018 NCCN 宫颈癌临床实践指南（第一版）》解读[J].中国实用妇科与产科杂志，2017，33（12）：1255-1261.
[9]	Therasse P，Arbuck SG，Eisenhauer EA，et al.New guidelines to evaluate the response to treatment in solid tumors[J].J Natl Cancer Inst，2000，92（3）：205-216.
[10]	Pelkofski E，Stine J，Wages NA，et al.Cervical cancer in women aged 35 years and younger[J].Clin Ther，2016，38（3）：459-466.
[11]	白璐，李雯慧，陈必良.宫颈癌新辅助化疗的现状与争议[J].现代肿瘤医学，2019，27（7）：1278-1280
[12]	李龙，赵娟，王月玲.腹腔镜下宫颈癌根治术30例临床分析[J].中国妇幼健康研究，2013，24（2）：261-263.
[13]	Colturato LF，Signorini Filho RC，Fernandes RC，et al.Lymph node micrometastases in initial stage cervical cancer and tumoral recurrence[J].Int J Gynaecol Obstet，2016，133（1）：69-75.
[14]	Ye Q，Yuan HX，Chen HL.Responsiveness of neoadjuvant chemotherapy before surgery predicts favorable prognosis for cervical cancer patients：a meta-analysis[J].J Cancer Res Clin Oncol，2013，139（11）：1887-1898.
[15]	Lapresa M，Parma G，Portuesi R，et al.Neoadjuvant chemotherapy in cervical cancer：an update[J].Expert Rev Anticancer Ther，2015，15（10）：1171-1181.
[19]	李仪.两种新辅助化疗方案治疗宫颈癌的回顾性研究[D].衡阳：南华大学，2016.
[26]	曹泽毅.减少子宫颈癌治疗后的未控和复发[J].中华妇产科杂志，2013，48（4）：302-303.
[16]	Scandurra G，Scibilia G，Banna GL，et al.Efficacy and tolerability of paclitaxel，ifosfamide，and cisplatin as a neoadjuvant chemotherapy in locally advanced cervical carcinoma[J].J Gynecol Oncol，2015，26（2）：118-124.
[17]	Gadducci A，Barsotti C，Laliscia C，et al.Dose-dense Paclitaxel-and Carboplatin-based Neoadjuvant Chemotherapy Followed by Surgery or Concurrent Chemo-radiotherapy in Cervical Cancer：a Preliminary Analysis[J].Anticancer Res，2017，37（3）：1249-1255.
[18]	Chen P，Jiao L，Wang DB.Squamous cell carcinoma antigen expression in tumor cells is associated with the chemosensitivity and survival of patients with cervical cancer receiving docetaxel-carboplatin-based neoadjuvant chemotherapy[J].Oncol Lett，2017，13（3）：1235-1241.
[20]	Kitagawa R，Katsumata N，Shibata T，et al.Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer：The Open-Label Randomized Phase ⅢTrial JCOG0505[J].J Clin Oncol，2015，33（19）：2129-2135.
[21]	Lorusso D，Petrelli F，Coinu A，et al.A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer[J].Gynecol Oneol，2014，133（1）：117-123.
[22]	Fei H，Ke P，Wang N，et al.An evaluation comparing Califomium252 neutron braehytherapy with neoadjuvant intraarterial embolism chemotherapy assisted surgery effect for treating advanced cervical carcinoma patients[J].Eur J Gynaecol Oncol，2015，36（4）：442-446.
[23]	Symonds RP，Gourley C，Davidson S，et al.Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer （CIRCCa）：a randomised，double-blind，placebo-controlled phase 2 trial[J].Lancet Oncol，2015，16（15）：1515-1524.
[24]	Ghezzi F，Cromi A，Ditto A，et al.Laparoscopic versus open radical hysterectomy for stage ⅠB2-ⅡB cervical cancer in the setting of neoadjuvant chemotherapy：a multi-institutional cohort study[J].Ann Surg Oncol，2013，20（6）：2007-2015.
[25]	Liang Y，Lü B，Chen X，et al.Prognostic value of pathological response to neoadjuvant chemotherapy in bulky stageⅠb2 and Ⅱa cervical squamous cell cancer patients[J].Virchows Arch，2016，468（3）：329-336.
[27]	Gupta S，Maheshwari A，Parab P，et al.Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2，ⅡA，or ⅡB squamous cervical cancer：a randomized controlled trial[J].J Clin Oncol，2018，36（16）：1548-1555.